Quick Answer
UroGen Pharma Ltd. reported Stockholders Equity of -$105.47 million for the year ending 2025.
- UroGen Pharma Ltd. showed a decrease of -1,098.2% in Stockholders Equity from 2024 to 2025.
- This data is from UroGen Pharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $123.87 million | Q2 2018: $113.55 million | Q3 2018: $103.58 million | Q1 2019: $239.59 million | Q2 2019: $224.78 million | Q3 2019: $210.92 million | Q1 2020: $150.45 million | Q2 2020: $142.66 million | Q3 2020: $120.53 million | Q1 2021: $76.49 million | Q2 2021: $56.27 million | Q3 2021: $31.54 million | Q1 2022: -$17.07 million | Q2 2022: -$40.91 million | Q3 2022: -$63.29 million | Q1 2023: -$116.55 million | Q2 2023: -$138.43 million | Q3 2023: -$41.99 million | Q1 2024: -$40.13 million | Q2 2024: $30.31 million | Q3 2024: $25.52 million | Q1 2025: -$46.46 million | Q2 2025: -$93.38 million | Q3 2025: -$115.41 million.
- Over the full 12 years of available data (2014 to 2025), UroGen Pharma Ltd.'s Stockholders Equity has declined by 3,434.6%.
- Historical annual values: Fiscal year 2025: -$105.47 million | Fiscal year 2024: -$8.80 million | Fiscal year 2023: -$65.21 million | Fiscal year 2022: -$89.36 million | Fiscal year 2021: $8.41 million | Fiscal year 2020: $96.36 million | Fiscal year 2019: $180.30 million | Fiscal year 2018: $90.09 million | Fiscal year 2017: $68.52 million | Fiscal year 2016: $16.31 million | Fiscal year 2015: $16.28 million | Fiscal year 2014: $3.16 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: